Roivant Sciences Ltd.
ROIV · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | -0.00 | -0.41 | -0.58 |
| FCF Yield | -11.53% | -9.38% | -16.27% | -21.01% |
| EV / EBITDA | -4.28 | -2.66 | -3.45 | -1.68 |
| Quality | ||||
| ROIC | -20.28% | 64.15% | -54.40% | -56.06% |
| Gross Margin | 96.86% | 95.11% | 78.58% | 83.78% |
| Cash Conversion Ratio | 2.35 | -0.18 | 0.76 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.02% | -16.05% | 37.07% | -6.52% |
| Free Cash Flow Growth | -10.10% | 10.45% | -23.15% | -24.59% |
| Safety | ||||
| Net Debt / EBITDA | 2.38 | 7.52 | 1.01 | 1.95 |
| Interest Coverage | 0.00 | 129.31 | -42.02 | -191.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.05 | 4.75 | 0.00 |
| Cash Conversion Cycle | -9,492.00 | -3,178.89 | -750.81 | -1,363.41 |